Please login to the form below

Not currently logged in
Email:
Password:

GSK settles Avandia cases for $60m

GSK has agreed to pay $60m to settle the first lawsuits alleging its diabetes drug, Avandia, causes heart attacks and strokes in some patients

GlaxoSmithKline (GSK) has agreed to pay around $60m to settle the first lawsuits alleging its Avandia (rosiglitazone) causes heart attacks and strokes in some patients.

According to people familiar with the case, the settlement would resolve more than 700 lawsuits related to the diabetes drug. Around 4,000 cases are yet to follow and GSK will face its first trial in a state court in Philadelphia, US, in July.

The US Food and Drug Administration (FDA) approved Avandia for sale in the US in 1999 and the drug amassed sales of $3bn by 2006, including sales of a combination of Avandia and another drug.

But in May 2007, the drug was linked to a 43 per cent increased risk of heart attacks and sales plummeted. Avandia was the world's best-selling diabetes pill before safety concerns emerged.

Analysts have predicted that GSK may face as much as $6bn in liability related to Avandia and there's a risk that US regulators may force the drug to be removed from the the market. The $60m settlement has been viewed positively by the market as it minimises risk.

The FDA is currently reviewing new and existing cardiovascular safety data of Avandia and expects to present an updated assessment of the risk and benefits of the drug at an advisory meeting scheduled for July.

11th May 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics